Answers are grounded in this paper and cite their sources.
African Americans are at higher risk of multiple myeloma (MM) yet underrepresented in clinical trials and reap less benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, providers, patients, industry partners and regulators at the FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a roadmap to addressing disparities broadly in clinical trials.
No takes yet. Share an insight, caveat, or question.
Gormley et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: